With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. More: Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
read moreSince 1999, Feb. 7 has marked National Black HIV/AIDS Awareness Day, drawing attention to the disproportionate impact of HIV on Black communities. More: How ViiV Healthcare plans to 'show up even better' in the fight against HIV in Black communities
read moreBain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mitsubishi Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group. The deal, which is expected to close in 2025’s third quarter, will set up
read moreRoche has detailed results of a phase 3 trial of its blood cancer drug Gazyva in lupus nephritis. The data set up the CD20 antibody for potential approval for what would be its most important indication. More: Roche details Gazyva's
read moreJohnson & Johnson’s proposed $14.6 billion purchase of Intra-Cellular Therapies took just one month from the time the buyer revealed its intention to the signing of the deal. The process involved a key intervention from J&J’s CEO Joaquin Duato, a
read moreThis week on “The Top Line,” we dig into the 10 biggest potential drug launches of 2025, predicted to rake in a combined $29 billion in annual sales by the end of the decade. More: Looking ahead at the most
read more© 1994 - 2026 B.M. Pharmaceuticals